The Visuo-Motor Attention Test in Boys with Attention Deficit Hyperactivity Disorder (ADHD): Methylphenidate-Placebo...

Area of Science:

• Neuroscience
• Developmental Psychology
• Pediatrics

Background:

• Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder characterized by inattention and/or hyperactivity-impulsivity.
• Visuomotor attention, the ability to process visual information and guide motor actions, is often impaired in children with ADHD.
• Methylphenidate (MPH) is a commonly prescribed stimulant medication for ADHD, but its specific effects on visuomotor attention require further investigation.

Purpose of the Study:

• To evaluate visuomotor attention abilities in boys with ADHD compared to typically developing controls.
• To assess the impact of Methylphenidate (MPH) versus placebo on visuomotor attention performance in children with ADHD.
• To investigate potential differences in MPH response among ADHD subtypes.

Main Methods:

• A randomized crossover design was employed with 36 boys diagnosed with ADHD and 36 age-matched controls.
• Participants completed the Visuomotor Attention Test (VMAT) at baseline and after one week of either MPH (immediate-release) or placebo.
• Statistical analyses compared VMAT performance between groups and across conditions.

Main Results:

• Children with ADHD demonstrated significantly poorer performance on several VMAT measures compared to controls at baseline.
• No significant baseline performance differences were found between ADHD subtypes (combined/hyperactive vs. inattentive).
• MPH treatment led to significant improvements in VMAT performance for the ADHD group, particularly for the combined and predominantly hyperactive (C/HI) subtype.

Conclusions:

• Visuomotor attention deficits are a key feature in boys with ADHD.
• The Visuomotor Attention Test (VMAT) is a sensitive tool for measuring attention deficits in ADHD.
• MPH treatment effectively enhances visuomotor attention in children with ADHD, with notable benefits for the C/HI subtype, suggesting its utility in treatment assessment.